ClinicalTrials.gg
CompletedNCT01827670Updated Jan 26, 2015Results posted

Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity

A Phase 3 interventional study of Stannous fluoride and Sodium monofluorophosphate in Dentine Hypersensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-26.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.

Enrollment
22nd of 28
119 · median 164
Started
2013
the only one that year
Phase 3
5 of 28
none open now
Registered
6th of 28
by date

Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 22nd largest by enrollment, is the only one that started in 2013, is one of 5 in phase 3, and was the 6th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →

Who these studies take

Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Dentin Sensitivity by GlaxoSmithKline as a file.
02

Study summary

Clinical studies have demonstrated long term relief from dentine hypersensitivity with twice daily brushing of a toothpaste containing stannous fluoride in comparison to marketed (negative) controls. The aim of this study is to evaluate the effectiveness of a stannous fluoride dentifrice in the treatment of dentinal hypersensitivity compared to a marketed (negative) control, over a period of 56 days (8 weeks) with twice daily brushing.

03

Conditions studied

  • Dentine Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with self-reported history of dentinal lasting more than 6 months but not more than 10 years.
  • Participants with minimum of 20 natural teeth.
  • At screening, a minimum of two accessible teeth (incisors, canines, premolars) that meet all of the following criteria.

    1. Teeth showing signs of facial/cervical gingival recession and/or signs of erosion or abrasion.
    2. Teeth with Gingival Index score ≤1 and a clinical mobility of ≤1.
    3. Teeth that are determined to be sensitive by the subject following a 1 second air blast to the cervical margin.

Exclusion criteria

Exclusion Criteria:

  • Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.
  • Any condition which, in the opinion of the investigator, causes dry mouth.
  • Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening.
  • Participant using of a desensitising dentifrice within 6 weeks of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    0.454% stannous fluoride dentifrice

    Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.

    Drug: Stannous fluoride

  • Active comparator
    0.76% sodium monofluorophosphate dentifrice

    Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.

    Drug: Sodium monofluorophosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Schiff Sensitivity Score

    The examiner conducted the evaporative air sensitivity assessment and scored the subject's response to the sensitivity stimulus using the four-point categorical Schiff Sensitivity Scale (SSS). Score 0 = Subject does not respond to air stimulus Score 1 = Subject responds to air stimulus, but does not request discontinuation of stimulus Score 2 = Subject responds to air stimulus, and requests discontinuation or moves from stimulus Score 3 = Subject responds to air stimulus, considers stimulus to be painful, and requests discontinuation

    Time frame: Baseline-Week 8

Secondary outcomes

  1. Mean Change From Baseline in Schiff Sensitivity Score

    The examiner conducted the evaporative air sensitivity assessment and scored the subject's response to the sensitivity stimulus using the four-point categorical Schiff Sensitivity Scale (SSS). Score 0 = Subject does not respond to air stimulus Score 1 = Subject responds to air stimulus, but does not request discontinuation of stimulus Score 2 = Subject responds to air stimulus, and requests discontinuation or moves from stimulus Score 3 = Subject responds to air stimulus, considers stimulus to be painful, and requests discontinuation

    Time frame: Baseline-Week 4

  2. Mean Change From Baseline in Tactile Sensitivity

    The examiner assessed the tactile sensitivity of eligible teeth using a Yeaple probe. The constant pressure applied by Yeaple probe probe allowed the examiner to vary the force applied to the dentin surface from 10g to an upper threshold of 80g, in increments of 10g. The greater the pressure the participant was able to tolerate, the less sensitive the tooth was considered. Testing began at 10g and increased by 10g, with each successive challenge, until either a "yes" response (pain was elicited) was recorded or the maximum force has been reached.

    Time frame: Baseline-Week 8

  3. Mean Change From Baseline in Tactile Sensitivity

    The examiner assessed the tactile sensitivity of eligible teeth using a Yeaple probe. The constant pressure applied by Yeaple probe probe allowed the examiner to vary the force applied to the dentin surface from 10g to an upper threshold of 80g, in increments of 10g. The greater the pressure the participant was able to tolerate, the less sensitive the tooth was considered. Testing began at 10g and increased by 10g, with each successive challenge, until either a "yes" response (pain was elicited) was recorded or the maximum force has been reached.

    Time frame: Baseline-Week 4

  4. Mean Change in Dentinal Hypersensitivity After 4 Weeks as Measured by Visual Analog Scale (VAS)

    The subject rated the intensity of their response to the evaporative air stimulus by rating the intensity of their response to the stimulus using a 100 millimeter (mm )VAS Scale 0 is No Pain and 100 is Worst Pain Imaginable A trained member of staff measured the line segment marked off in mm and recorded this measurement in the CRF

    Time frame: Baseline-Week 4

  5. Mean Change in Dentinal Hypersensitivity After 8 Weeks as Measured by Visual Analog Scale (VAS)

    The subject rated the intensity of their response to the evaporative air stimulus by rating the intensity of their response to the stimulus using a 100 millimeter (mm )VAS Scale 0 is No Pain and 100 is Worst Pain Imaginable A trained member of staff measured the line segment marked off in mm and recorded this measurement in the CRF

    Time frame: Baseline - Week 8

07

Results

Posted Jan 26, 2015

Participant flow

Participants were recruited at the clinical site.

Participant flow — Overall Study
MilestoneControl Dentifrice (0.76% Sodium Monofluorophosphate)Test Dentifrice (0.454% Stannous Fluoride)
Started6059
Completed5756
Not completed33
Withdrew: Withdrawal of consent32
Withdrew: Lost to follow-up01

Outcome measures

PrimaryMean Change From Baseline in Schiff Sensitivity Score

The examiner conducted the evaporative air sensitivity assessment and scored the subject's response to the sensitivity stimulus using the four-point categorical Schiff Sensitivity Scale (SSS). Score 0 = Subject does not respond to air stimulus Score 1 = Subject responds to air stimulus, but does not request discontinuation of stimulus Score 2 = Subject responds to air stimulus, and requests discontinuation or moves from stimulus Score 3 = Subject responds to air stimulus, considers stimulus to be painful, and requests discontinuation

Time frame:
Baseline-Week 8
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Schiff Sensitivity Score
Score on a scaleControl Dentrifice (0.76% Sodium Monofluorophosphate)Test Dentrifice (0.454% Stannous Fluoride)
Schiff Sensitivity Score at Baseline2.26 ± 0.3792.25 ± 0.355
Schiff Sensitivity Score at Week 82.09 ± 0.6280.78 ± 0.687
Statistical analysis
  • Control Dentrifice (0.76% Sodium Monofluorophosphate) vs Test Dentrifice (0.454% Stannous Fluoride) · ANCOVA · p = <0.0001 · Adjusted mean: -1.29 · 95% CI -1.53 to -1.06Difference was 0.454% stannous fluoride minus 0.76% sodium monofluorophosphate such that a negative difference favours first named treatment.
SecondaryMean Change From Baseline in Schiff Sensitivity Score

The examiner conducted the evaporative air sensitivity assessment and scored the subject's response to the sensitivity stimulus using the four-point categorical Schiff Sensitivity Scale (SSS). Score 0 = Subject does not respond to air stimulus Score 1 = Subject responds to air stimulus, but does not request discontinuation of stimulus Score 2 = Subject responds to air stimulus, and requests discontinuation or moves from stimulus Score 3 = Subject responds to air stimulus, considers stimulus to be painful, and requests discontinuation

Time frame:
Baseline-Week 4
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in Schiff Sensitivity Score
Score on a ScaleControl Dentrifice (0.76% Sodium Monofluorophosphate)Test Dentrifice (0.454% Stannous Fluoride)
Schiff Sensitivity Score at Baseline2.26 ± 0.3792.25 ± 0.355
Schiff Sensitivity Score at Week 42.10 ± 0.6011.27 ± 0.598
Statistical analysis
  • Control Dentrifice (0.76% Sodium Monofluorophosphate) vs Test Dentrifice (0.454% Stannous Fluoride) · ANCOVA · p = <0.0001 · Adjusted mean: -0.81 · 95% CI -1.00 to -0.62Difference was 0.454% Stannous Fluoride minus 0.76% Sodium MonoFluorophosphate such that a negative difference favored first named treatment
SecondaryMean Change From Baseline in Tactile Sensitivity

The examiner assessed the tactile sensitivity of eligible teeth using a Yeaple probe. The constant pressure applied by Yeaple probe probe allowed the examiner to vary the force applied to the dentin surface from 10g to an upper threshold of 80g, in increments of 10g. The greater the pressure the participant was able to tolerate, the less sensitive the tooth was considered. Testing began at 10g and increased by 10g, with each successive challenge, until either a "yes" response (pain was elicited) was recorded or the maximum force has been reached.

Time frame:
Baseline-Week 8
Reported as:
Mean · Grams
Mean Change From Baseline in Tactile Sensitivity
GramsControl Dentrifice (0.76% Sodium Monofluorophosphate)Test Dentrifice (0.454% Stannous Fluoride)
Tactile Threshold at Baseline (g)10.1 ± 0.6610.4 ± 1.43
Tactile Threshold at Week 8 (g)14.6 ± 13.7741.6 ± 25.85
Statistical analysis
  • Control Dentrifice (0.76% Sodium Monofluorophosphate) vs Test Dentrifice (0.454% Stannous Fluoride) · ANCOVA · p = <0.0001 · Adjusted mean difference: 27.2 · 95% CI 19.4 to 35.1Difference was 0.454% Stannous Fluoride minus 0.76% Sodium MonoFluorophosphate such that a positive difference favours first named treatment.
SecondaryMean Change From Baseline in Tactile Sensitivity

The examiner assessed the tactile sensitivity of eligible teeth using a Yeaple probe. The constant pressure applied by Yeaple probe probe allowed the examiner to vary the force applied to the dentin surface from 10g to an upper threshold of 80g, in increments of 10g. The greater the pressure the participant was able to tolerate, the less sensitive the tooth was considered. Testing began at 10g and increased by 10g, with each successive challenge, until either a "yes" response (pain was elicited) was recorded or the maximum force has been reached.

Time frame:
Baseline-Week 4
Reported as:
Mean · Grams
Mean Change From Baseline in Tactile Sensitivity
GramsControl Dentrifice (0.76% Sodium Monofluorophosphate)Test Dentrifice (0.454% Stannous Fluoride Dentifrice)
Tactile Thresold (g) at Baseline10.1 ± 0.6610.4 ± 1.43
Tactile Thresold (g) at Week 415.8 ± 14.7824.6 ± 17.53
Statistical analysis
  • Control Dentrifice (0.76% Sodium Monofluorophosphate) vs Test Dentrifice (0.454% Stannous Fluoride Dentifrice) · ANCOVA · p = 0.0138 · Adjusted mean: 7.5 · 95% CI 1.6 to 13.4Difference was 0.454% Stannous Fluoride minus 0.76% Sodium MonoFluorophosphate such that a positive difference favours first named treatment.
SecondaryMean Change in Dentinal Hypersensitivity After 4 Weeks as Measured by Visual Analog Scale (VAS)

The subject rated the intensity of their response to the evaporative air stimulus by rating the intensity of their response to the stimulus using a 100 millimeter (mm )VAS Scale 0 is No Pain and 100 is Worst Pain Imaginable A trained member of staff measured the line segment marked off in mm and recorded this measurement in the CRF

Time frame:
Baseline-Week 4
Reported as:
Mean · Score on a Scale
Mean Change in Dentinal Hypersensitivity After 4 Weeks as Measured by Visual Analog Scale (VAS)
Score on a ScaleControl Dentrifice (0.76% Sodium Monofluorophosphate)Test Dentrifice (0.454% Stannous Fluoride)
VAS Score at Baseline58.40 ± 21.66158.26 ± 21.099
VAS Score at week 450.32 ± 23.25738.09 ± 21.612
Statistical analysis
  • Control Dentrifice (0.76% Sodium Monofluorophosphate) vs Test Dentrifice (0.454% Stannous Fluoride) · ANCOVA · p = 0.0003 · Adjusted mean: -12.14 · 95% CI -18.51 to -5.77Difference was 0.454% Stannous Fluoride minus 0.76% Sodium MonoFluorophosphate such that a negative difference favored first named treatment
SecondaryMean Change in Dentinal Hypersensitivity After 8 Weeks as Measured by Visual Analog Scale (VAS)

The subject rated the intensity of their response to the evaporative air stimulus by rating the intensity of their response to the stimulus using a 100 millimeter (mm )VAS Scale 0 is No Pain and 100 is Worst Pain Imaginable A trained member of staff measured the line segment marked off in mm and recorded this measurement in the CRF

Time frame:
Baseline - Week 8
Reported as:
Mean · Score on a Scale
Mean Change in Dentinal Hypersensitivity After 8 Weeks as Measured by Visual Analog Scale (VAS)
Score on a ScaleControl Dentrifice (0.76% Sodium Monofluorophosphate)Test Dentrifice (0.454% Stannous Fluoride)
VAS Score at Baseline58.40 ± 21.66158.26 ± 21.099
VAS Score at Week 843.94 ± 23.99622.17 ± 22.299
Statistical analysis
  • Control Dentrifice (0.76% Sodium Monofluorophosphate) vs Test Dentrifice (0.454% Stannous Fluoride) · ANCOVA · p = <0.0001 · Adjusted mean: -21.82 · 95% CI -29.55 to -14.09Difference was 0.454% Stannous Fluoride minus 0.76% Sodium MonoFluorophosphate such that a negative difference favored first named treatment

Adverse events

Collected over All Adverse events encountered or spontaneously reported following use of dentifices were reported at Baseline visit(Visit 2), 28 days(Visit 3) and Visit 4(Day 56). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Dentifrice (0.76% Sodium Monofluorophosphate)—0/60 (0%)2/60 (3.3%)
Test Dentifrice (0.454% Stannous Fluoride)—0/59 (0%)1/59 (1.7%)
Most frequent other events
Most frequent other events
EventControl Dentifrice (0.76% Sodium Monofluorophosphate)Test Dentifrice (0.454% Stannous Fluoride)
DysgeusiaGeneral disorders0/601/59
Mouth InjuryGeneral disorders1/600/59
InfluenzaRespiratory, thoracic and mediastinal disorders1/600/59

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Control Dentifrice (0.76% Sodium Monofluorophosphate)Test Dentifrice (0.454% Stannous Fluoride)Total
Mean43.1 ± 12.2742.2 ± 11.2742.6 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Control Dentifrice (0.76% Sodium Monofluorophosphate)Test Dentifrice (0.454% Stannous Fluoride)Total
Female43 ± 75.446 ± 80.789
Male14 ± 24.611 ± 19.325
08

Study locations

1 site
  • Salus Research, Inc.
    Fort Wayne, Indiana 46825, United States
09

References and documents

Publications

  • Parkinson CR, Jeffery P, Milleman JL, Milleman KR, Mason S. Confirmation of efficacy in providing relief from the pain of dentin hypersensitivity of an anhydrous dentifrice containing 0.454% with or without stannous fluoride in an 8-week randomized clinical trial. Am J Dent. 2015 Aug;28(4):190-6. PubMed 26437498 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2013
First posted
Apr 9, 2013
Start
Feb 2013
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Jan 26, 2015
Last update
Jan 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01827670
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 9, 2013
Start date
Feb 2013
Primary completion
May 2013
Completion
May 2013
Results posted
Jan 26, 2015
Last update
Jan 26, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion